(Total Views: 254)
Posted On: 02/23/2018 3:09:13 PM
Post# of 72440
Welcome Daubers! I had Cabel ask Leo on the status of oral K formulation. He usually gets a reply but not this time. Base on the most recent PR, the pre-clinical studies are still ongoing.
“With the positive observation of intra-tumor p53 modulation, the Company will now allocate resources to focus its efforts on completing development of an oral formulation, including performing bridging toxicology work.”
http://www.ipharminc.com/press-release/2018/2...3-observed
“With the positive observation of intra-tumor p53 modulation, the Company will now allocate resources to focus its efforts on completing development of an oral formulation, including performing bridging toxicology work.”
http://www.ipharminc.com/press-release/2018/2...3-observed
(0)
(0)
Scroll down for more posts ▼
